Merck preview: focus on post-Keytruda growth path

February 2, 2026 10:00 PM

Investing.com -- Merck (NYSE: MRK) fourth-quarter results are expected to frame how the company plans to manage looming Keytruda declines ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found